Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Mayo Foundation

Neither a doctor nor a teaching hospital

Research payments

$2,876,708

201 payments

Through program year 2025, Mayo Foundation is reported as receiving $2,876,708 in research payments, across 201 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,273,027 63
2024 Research $68,432 1
2023 Research $49,500 1
2022 Research $63,608 5
2021 Research $412,447 20
2020 Research $456,245 52
2019 Research $553,449 59

Breakdown

Who paid Research payments · program years 2019–2025
  1. Medtronic, Inc. $928,275 58 payments
  2. Pfizer Inc. $566,819 36 payments
  3. Astellas Pharma Global Development $462,684 7 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $329,574 33 payments
  5. MorphoSys AG $243,560 12 payments
  6. Shire North American Group Inc $239,045 39 payments
  7. Roche Products Limited $61,696 4 payments
  8. Array BioPharma Inc. $32,780 7 payments
  9. Celgene Corporation $6,750 1 payment
  10. Janssen Research & Development, LLC $4,714 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Retrospective Study of Claudin 18.2 (CLDN18.2) Expression Prevalence, Prognostic Value and Associated Clinical Features in Advanced Pancreatic Adenocarcinoma $413,184 6 payments
  2. Expand II $390,291 8 payments
  3. A Phase 3 Multicenter Randomized Doubleblind Extension Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf06291826 20 MG Or 80 MG in Subjects Diagnosed With Transthyretin Cardiomyopathy Ttrcm $322,232 24 payments
  4. A Phase Ib, open-label, randomized study to assess safety and preliminary efficacy of Tafasitamab in addition to R-CHOP or Tafasitamab plus Lenalidomide in addition to R-CHOP in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) $239,956 11 payments
  5. A Phase 3 Multinational Randomized Openlabel Parallelarm Study of Avelumab Msb0010718c in Combination With Axitinib Inlytaregistered Versus Sunitinib Sutentregistered Monotherapy in the Firstline Treatment of Patients With Advanced Renal Cell Carcinoma $235,937 10 payments
  6. A Phase 3, Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus Mln9708 Or Physicians Choice of Treatment Administered to Patients With Relapsed Or Refractory Systemic Light Chain (Al) Amyloidosis $232,495 13 payments
  7. Perigon $228,450 14 payments
  8. TAVR Low Risk $145,598 10 payments
  9. Oral Budesonide Suspension Obs in Adolescents and Adult Subjects With Eosinophilic Esophagitis DB, Maintenance $142,228 8 payments
  10. Avalus Ultra PAS $74,200 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record